Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb

by

  1. Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial Bristol-Myers Squibb
  2. Bristol Myers’ Opdivo stages comeback in bladder cancer, teeing up 2 ‘Merck’ showdowns FiercePharma
  3. Bristol Myers’ Opdivo extends survival in bladder cancer study Reuters
  4. First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma OncLive
  5. Study: Bladder Cancer Drug Extends Survival Newsmax

Read original article here

Leave a Comment